|
|
|
Sunday, February 27, 2011 — 7:30 p.m., CC 006 C/D
|
- Gene Patents: The Future of Gene Research in an Era of Patents- Scientific and Legal Considerations
|
|
Moderator:
|
Jennifer L. Hunt, Massachusetts General Hospital, Boston, MA
|
|
|
Disclosure:
|
In accordance with ACCME guidelines regarding disclosure, the USCAP policy requires that faculty members who have a significant financial or other relationship with a commercial company, entity, or service (which will be discussed in this Symposium) must disclose this to attendees. The Academy also requires that speakers disclose any products that are not labeled for the use under discussion. The speakers listed below have indicated they have nothing to disclose.
|
Click the button above to add this event to your Itinerary Planner...
| 7:30 |
Introduction:
- Jennifer L. Hunt, Massachusetts General Hospital, Boston, MA |
| 7:45 |
The Legal History of Gene Patents
- Roger Klein, Blood Center of Wisconsin, Milwaukee, WI |
| 8:15 |
Impact of Gene Patents on Genetic Innovation and Research
- Debra G. Leonard, Weill Cornell Medical College, New York, NY |
| 8:45 |
Clinical Implications of Gene Patenting
- Mark H. Stoler, University of Virginia Health System, Charlottesville, VA |
| 9:15 | Panel Discussion |
This symposium will provide an overview of gene patent history and describe the current lawsuit challenging the legality of patents on human genes- specifically, patents covering the BRCA1 and BRCA2 genes, which are associated with breast and ovarian cancer. The lawsuits multiple stages and outcomes are closely being followed by the entire pathology field to determine the implications it will have on the field of pathology and laboratory medicine.
The symposium's objective is to: 1) Outline how patents stifle the innovative and research processes, negating further refinement in test methodology and improvements in quality. 2) Inform the audience how gene patents potentially impact patients' rights by denying them access to their own genetic information and access to testing for the uninsured as well as those whose health care coverage requires that testing be reimbursed by a third-party payer.
The topics were selected by leaders of the Association for Molecular Pathology and American Society for Clinical Pathology who are also USCAP members. |
|
|
|
